MENU
+Compare
CSBR
Stock ticker: NASDAQ
AS OF
Jun 27, 01:39 PM (EDT)
Price
$7.41
Change
+$0.19 (+2.63%)
Capitalization
99.83M

CSBR stock forecast, quote, news & analysis

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs... Show more

Industry: #Biotechnology
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CSBR with price predictions
Jun 26, 2025

CSBR sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for CSBR moved below the 200-day moving average on June 10, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CSBR moved out of overbought territory on June 23, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where CSBR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CSBR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CSBR broke above its upper Bollinger Band on June 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 03, 2025. You may want to consider a long position or call options on CSBR as a result. In of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CSBR moved above its 50-day moving average on June 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CSBR crossed bullishly above the 50-day moving average on June 17, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CSBR advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 115 cases where CSBR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CSBR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.248) is normal, around the industry mean (16.566). P/E Ratio (16.044) is within average values for comparable stocks, (58.942). CSBR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.298). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (1.724) is also within normal values, averaging (254.026).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CSBR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.32B. The market cap for tickers in the group ranges from 151 to 301.01B. NONOF holds the highest valuation in this group at 301.01B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 10%. For the same Industry, the average monthly price growth was 39%, and the average quarterly price growth was 17%. RKVTD experienced the highest price growth at 995%, while ICU experienced the biggest fall at -57%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 110%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 60
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of advanced technology solutions and services for oncology drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
One University Plaza
Phone
+1 201 808-8400
Employees
230
Web
https://www.championsoncology.com